SGRY - Surgery Partners reaffirmed FY20 adj. EBITDA guidance provides FY21 initial adj. EBITDA outlook

For FY20, Surgery Partners (SGRY) provided revenue guidance of ~$1.86B and reaffirmed its previous FY20 adj. EBITDA guidance range of $250 to $260M.Consistent with previous management statements, the company projects that in 2021, it will re-establish the multi-year double-digit; adj. growth trajectory and profit levels originally targeted based on a pre-COVID baseline. The company is well positioned to capture $90B+ existing outpatient surgical market and ~$60B of cases migrating to outpatient.2021 Adj. EBITDA is projected to be ~$315M.Dig in more details at its Corporate Presentation.Earnings are scheduled for Feb.4.

For further details see:

Surgery Partners reaffirmed FY20 adj. EBITDA guidance, provides FY21 initial adj. EBITDA outlook